Autopsy report · NCT01452516
Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions
Cause of deathSlow enrollment
“Study was terminated due to slow accrual rate.”
Life of this trial
- Registered 1 year 2 months after it had already started.
- Ran for about 3 years 2 months before it stopped.
- 28 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- Pioneer Surgical Technology, Inc.
- Sponsor type
- Industry
- Conditions
- Degenerative Disc Disease; Spinal Stenosis; Spondylolisthesis
- Interventions
- nanOss Bioactive Bone void filler; Interbody FCage
- Participants
- 28
- Sites
- 7
- Countries
- United States
Trials that died the same way
- LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
“Study was terminated due to slow accrual.” - Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
“Study terminated due to slow accrual.” - CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
“Study terminated due to slow/insufficient accrual.” - Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
“Study terminated due to low accrual.” - Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension
“Study has been terminated due to poor accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.